Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...
Today, majors across segments including Parle Industries, Easy Trip Planners, Bajaj Consumer Care, Aditya Birla Fashion & ...
MTN Nigeria CEO Karl Toriola has defended recent tariff hikes by mobile network operators, stating they are essential for the ...
A TASKFORCE will aim to allocate £2 million to a successful project in Ulverston by June as a ‘lasting legacy’ from a pharmaceutical ...
About the Cystic Fibrosis Trust Cystic Fibrosis Trust is the only UK-wide charity dedicated to uniting for a life unlimited for everyone affected by cystic fibrosis. The Trust funds cutting edge ...
GlaxoSmithKline has found a replacement for ... His time at Pfizer has coincided with the spectacular success of its BioNTech-partnered mRNA vaccine for COVID-19 – Comirnaty – and as GSK ...
Westmorland and Furness Council has approved a planning application from applicants, named as Ms and Mr A and D Atkinson and Robinson, to allow indoor sport, fitness and the provision of medical ...
If he Nifty-50 index breaks the 22800 support zone then it could slip till 22600-22500. On the other side, 23000 is an ...